Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions

Archives of Dermatology

Volumn 143, Issue 2, 2007, Pages 223-231

  De Gannes, Gillian C ^a   Ghoreishi, Mehran ^a   Pope, Janet ^b   Russell, Anthony ^c   Bell, David ^b   Adams, Stewart ^d   Shojania, Kamran ^a   Martinka, Magdalena ^e   Dutz, Jan P ^a,f  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e VANCOUVER GENERAL HOSPITAL   (Canada)

^f Skin Care Center   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADALIMUMAB; CALCIPOTRIOL; CELECOXIB; ETANERCEPT; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETIDRONIC ACID; FENOFIBRATE; INFLIXIMAB; LEFLUNOMIDE; METFORMIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAPROXEN; PREDNISONE; RAMIPRIL; ROFECOXIB; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VITAMIN;

ADULT; AGED; ARTHRITIS; ARTICLE; CLINICAL ARTICLE; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; HERPES SIMPLEX; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; IMMUNOREGULATION; LOW DRUG DOSE; MALE; PAPULAR RASH; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; PUSTULOSIS PALMOPLANTARIS; RHEUMATOID ARTHRITIS; SKIN BIOPSY; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; DRUG ERUPTIONS; FEMALE; HUMANS; MIDDLE AGED; PSORIASIS; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846974080     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.2.223     Document Type: Article

References (35)

1. Adams DR, Buckel T, Sceppa JA. Infliximab-associated new-onset psoriasis. J Drugs Dermatol. 2006;5:178-179.
2. Baeten D, Kruithof E, Van den Bosch F, et al. Systematic safety follow-up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis. 2003;62:829-834.
3. Dereure O, Guillot B, Jorgensen C, Cohen JD, Combes B, Guilhou JJ. Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases. Br J Dermatol. 2004;151:506-507.
4. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7:R666-R676.
5. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139:1627-1632.
6. Grinblat B, Scheinberg M. Unexpected onset of psoriasis during infliximab treatment: comment on the article by Beuthien et al. Arthritis Rheum. 2005;52:1333-1334.
7. Haibel H, Spiller I, Strasser C. Unexpected new onset or exacerbating of psoriasis in treatment of active ankylosing spondylitis with TNF-alpha blocking agents [abstract]. Ann Rheum Dis. 2004;63(suppl):405.
8. Kary S, Worm M, Audring H, et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis. 2006;65:405-407.
9. Kary S, Worm M, Fritz J, et al. New onset of aggravating of psoriatic skin lesions in patients with definitive rheumatoid arthritis under treatment with TNF-alpha antagonists: report of 8 cases [abstract]. Ann Rheum Dis. 2004;63(suppl):276.
10. Michaelsson G, Kajermo U, Michaelsson A, Hagforsen E. Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct? Br J Dermatol. 2005;153:1243-1244.
11. Peramiquel L, Puig L, Dalmau J, Ricart E, Roe E, Alomar A. Onset of flexural psoriasis during infliximab treatment for Crohn's disease. Clin Exp Dermatol. 2005;30:713-714.
12. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 2005;52:2513-2518.
13. Starmans-Kool MJ, Peeters HR, Houben HH. Pustular skin lesions in patients treated with infliximab: report of two cases. Rheumatol Int. 2005;25:550-552.
14. Thurber M, Feasel A, Stroehlein J, Hymes SR. Pustular psoriasis induced by infliximab. J Drugs Dermatol. 2004;3:439-440.
15. Chustecka Z Psoriasis with TNF inhibitors: Is there an infectious etiology. http//www.jointandbone.org/viewArticle.do?primaryKey=569511. Accessed October 6, 2005.
16. Gilliet M, Conrad C, Geiges M, et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol. 2004;140:1490-1495.
17. Boyman O, Hefti HP, Conrad C, Nickoloff BJ, Suter M, Nestle FO. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med. 2004;199:731-736.
18. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357:1842-1847.
19. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385-390.
20. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med. 2005;202:135-143.
21. Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A. 2005;102:3372-3377.
22. Fah J, Pavlovic J, Burg G. Expression of MxA protein in inflammatory dermatoses. J Histochem Cytochem. 1995;43:47-52.
23. von Wussow P, Jakschies D, Hochkeppel HK, Fibich C, Penner L, Deicher H. The human intracellular Mx-homologous protein is specifically induced by type I interferons. Eur J Immunol. 1990;20:2015-2019.
24. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest. 2004;113:1664-1675.
25. Nestle FO, Gilliet M. Defining upstream elements of psoriasis pathogenesis: an emerging role for interferon alpha. J Invest Dermatol. 2005;125:xiv-xv.
26. Ladoyanni E, Nambi R. Psoriasis exacerbated by interferon-alpha in a patient with chronic myeloid leukemia. J Drugs Dermatol. 2005;4:221-222.
27. van der Fits L, van der Wel LI, Laman JD, Prens EP, Verschuren MC. In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. J Invest Dermatol. 2004;122:51-60.
28. Eriksen KW, Lovato P, Skov L, et al. Increased sensitivity to interferon-alpha in psoriatic T cells. J Invest Dermatol. 2005;125:936-944.
29. Vermi W, Bonecchi R, Facchetti F, et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol. 2003;200:255-268.
30. Aeberli D, Seitz M, Juni P, Villiger PM. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors. Rheumatology (Oxford). 2005;44:172-175.
31. Pascual V, Banchereau J, Palucka AK. The central role of dendritic cells and interferon-alpha in SLE. Curr Opin Rheumatol. 2003;15:548-556.
32. Wenzel J, Worenkamper E, Freutel S, et al. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol. 2005;205:435-442.
33. Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005;57:664-678.
34. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum. 2005;52:2192-2201.
35. De Bandt M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005;7:R545-R551.